PROGRAM CHAIRS
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California
Vallejo, California
Emily K. Sims, MD, MS
Associate Professor of Pediatrics
Pediatric Endocrinology and Diabetology
Center for Diabetes and Metabolic Diseases
Indiana University School of Medicine
Assistant Director of Faculty Development and Translational Research
Herman B Wells Center for Pediatric Research
Associate Director, IU Medical Scientist Training Program
Indianapolis, Indiana
SPEAKING FACULTY
Kim Pfotenhauer, DO, FACOFP, DABOM
Assistant Professor
Assistant Dean for Clerkship Education
Michigan State University College of Osteopathic Medicine
East Lansing, Michigan
Lucia Novak, MSN, ANP-BC, BC, ADM, CDTC
President, Diabesity, LLC
Co-Executive Director, Capital Health & Metabolic Center
Capital Diabetes & Endocrine Associates
Silver Spring, Maryland
PATIENT CAREGIVER
Tonya McNeal
Washington, D.C.
PROGRAM OVERVIEW
The DETECT T1D enduring activity unites multidisciplinary faculty and a type 1 diabetes (T1D) patient advocate to explore practical strategies for screening, follow-up, early referral, and treatment to delay T1D progression. The program addresses clinician and patient challenges to enhance early identification and optimize patient selection. Additionally, it provides access to our website with educational aids and resources to reinforce engagement and deepen understanding of evolving concepts in early-stage T1D management.
TARGET AUDIENCE
This enduring activity is designed to meet the educational needs of multidisciplinary clinicians involved in the care of patients with or at high risk for T1D. The intended audience includes primary care clinicians, pediatricians, pediatric and adult endocrinologists, diabetes educators, infusion professionals, and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this enduring activity, attendees will have improved ability to:
- Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
- Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection
- Develop workflows to appropriately monitor, follow-up, or refer individuals who are screened for T1D
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions
- Develop strategies for establishing referral pathways and enhancing collaboration with specialists to enable earlier application of disease-modifying therapies for early-stage T1D
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of up to 2.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 2.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Jay Shubrook, DO | Consulting fees: Abbott, Bayer, Eli Lilly, Insulet, Madrigal, Novo Nordisk, and Sanofi Fees for Non-CME/CE Services: Corcept Therapeutics Contracted Research: Breakthrough T1D |
| Emily Sims, MD | Consulting fees: Diamond, Sanofi, Wink Therapeutics |
| Kim Pfotenhauer, DO | Consulting fees: Novo Nordisk Ownership interests: ROMTech |
| Lucia Novak, MSN | Consulting fees: Ascencia Diabetes Care Speaker’s bureaus: Abbott, Novo Nordisk, Sanofi, Nestlé Health Science |
| Tonya McNeal | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Marissa Mays-Verman, Program Director for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
- Naomi DeBrito, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Manager for Med Learning Group, has nothing to disclose.
- Melanie Grau, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This enduring activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 07, 2025
EXPIRATION DATE: November 07, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
